’This book admirably covers prostate cancer. It is written in an easily digestible manner for non-experts and emphasizes the importance of a team approach to treatment of patients with this disease.’–Doody’s Reviews
With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence-based approaches to prostate cancer treatment. The book provides a comprehensive view of the entire spectrum of prostate cancer management from initial screening through novel and experimental treatments that have the potential for a major impact on practice.
The book first reviews fundamental issues including epidemiology, screening, risk reduction, diagnosis and pathologic characterization, staging, and imaging. This includes strategies for improving the accuracy of PSA screening and an update on controversies surrounding the ISUP Modified Gleason Score. The book covers novel molecular and genotype profiling in prostate cancer, including morphometric and systems pathology. Detailed information is provided on radiographic imaging for diagnosis and staging. The treatment sections of the book correspond to the staging of disease. The treatment of localized disease addresses the range of multidisciplinary management options including a discussion of prostate cancer’s impact on the quality of life. A detailed review of multimodal therapies (medical, surgical, and radiologic) addresses the treatment of localized advanced disease, and coverage of advanced metastatic prostate cancer reviews current management options including a range of promising novel and experimental agents. The book also discusses counseling the high-risk patient. Several chapters incorporate models of care delivery, patient navigation for multidisciplinary care, genomic and risk assessment, and comparative effects of research in treatment decision-making. The book is designed as a management text for all health care professionals who provide care for prostate cancer patients as well as patients, families, and advocates. Extensive references offer opportunities for additional study.
Key Features:
- Delineates a practical, concise approach to multidisciplinary management of prostate cancer
- Provides a wide range of perspectives and expertise
- Written and edited by an international, multidisciplinary team of prostate cancer specialists
- Focuses on such key issues as special populations, screening controversies, patient counseling, and quality of life
- Includes discussion of important emerging topics such as gene profiling and targeted therapies and comparative effectiveness data
Innehållsförteckning
Contributors
Series Foreword
Preface
Acknowledgments
I.
Epidemiology, Screening, and Diagnosis
1 Introduction: The Multidisciplinary Approach to Prostate Cancer
Leonard G. Gomella
2.1 Epidemiology of Prostate Cancer
Kathryn M. Wilson
Lorelei A. Mucci
2.2 Diet and Prostate Cancer
James R. Marshall
2.3 Epidemiology: Obesity as a Risk Factor
Emma H. Allott
Stephen J. Freedland
3.1.1 Screening and Diagnosis: The Pros of PSA Screening
Janine L. Oliver
Gurdarshan S. Sandhu
Gerald L. Andriole
Robert L. Grubb III
3.1.2 The Argument Against Prostate Cancer Screening
Otis W. Brawley
3.1.3 How Do We Improve PSA Accuracy?
Toru Sugihara
Michael W. Kattan
3.2 Screening and Diagnosis: An Update on the ISUP-Modified Gleason Score and Its Controversies
Ibrahim Kulac
Angelo M. De Marzo
3.3 Evaluation of Distant Disease: The Utility of Nuclear Imaging
Dima Raskolnikov
Baris Turkbey
Liza Lindenberg
Peter L. Choyke
Peter A. Pinto
4 Current Approaches to Prostate Cancer Staging and Risk Stratification: In the Midst of a Paradigm Shift
Chad A. Reichard
Eric A. Klein
5.1 Novel Molecular and Genotype Profiling in Prostate Cancer: The Future of Screening, Diagnosis, and Staging
Heesun Shin
Ismael A. Vergara
Anirban P. Mitra
Timothy J. Triche
Elai Davicioni
5.2 Genomics and Risk Assessment
Hao G. Nguyen
Matthew R. Cooperberg
Peter R. Carroll
5.3 Future Direction: Novel Urine and Serum Markers
Waleed A. Hassen
5.4 Morphometric and Systems Pathology: The Future of Screening, Diagnosis, and Staging
Michael J. Donovan
Faisal M. Khan
Richard Scott
Gerardo Fernandez
Carlos Cordon-Cardo
5.5.1 PET: The Future of Screening, Diagnosis, and Staging for Prostate Cancer
Mathew L. Thakur
Edouard J. Trabulsi
Sung M. Kim
Charles M. Intenzo
Leonard G. Gomella
5.5.2 DCE MRI and MR Spectroscopy: The Future of Screening, Diagnosis, and Staging
Victor Sai
Antonio C. Westphalen
5.5.3 Future Direction: Contrast Ultrasound 109
Sanjay Kasturi
Edouard J. Trabulsi
Ethan J. Halpern
6 Counseling Patients With Clinically Localized, High-Risk Prostate Cancer
Jonathan L. Silberstein
James A. Eastham
II.
Treatment for Low-Risk, Localized Disease
7 Active Surveillance for Prostate Cancer: An Overview
Laurence Klotz
8 Treatment of Low-Risk, Localized Prostate Cancer: A Holistic Approach With Diet
Jillian Scambia
Annie DarvesñBornoz
Aaron Katz
9.1 Traditional Radical Prostatectomy
Zachary L. Smith
Thomas J. Guzzo
9.2 Laparoscopic Radical Prostatectomy: Techniques and Complications
Fernando Pablo Secin
Karim Touijer
9.3 Robotic Radical Prostatectomy: The Thomas Jefferson University Experience
Costas D. Lallas
Edouard J. Trabulsi
9.4 Surgical Training, Digital Capture, Virtual Reality, and the Future of Radical Prostatectomy
Costas D. Lallas
10.1.1 External Beam Radiation Therapy: Conventional Fractionation
David E. Greene
Richard K. Valicenti
10.1.2 Hypofractionated Radiation Therapy for Localized Prostate Cancer
Nicholas G. Zaorsky
Robert B. Den
10.1.3 Stereotactic Body Radiation Therapy for Localized Prostate Cancer
Nicholas G. Zaorsky
Robert B. Den
10.1.4 Treatment of Low-Risk, Localized Prostate Cancer: Use of Proton Therapy
Phillip J. Gray
Ayal A. Aizer
Jason A. Efstathiou
10.2 Treatment of Low-Risk, Localized Prostate Cancer: Brachytherapy
Peter Grimm
11.1 Treatment of Low-Risk, Localized Prostate Cancer: General Principles of Ablative and Focal Therapies
Joshua A. Cohn
Aytekin Oto
Scott E. Eggener
11.2 Hyperthermia for Prostate Cancer
Mark Hurwitz
11.3 Ablative Techniques: Vascular Targeted Photodynamic Therapy
Ashley G. Winter
Jonathan A. Coleman
11.4 Laser Ablative Techniques for Prostate Cancer
Ashley G. Winter
Jonathan A. Coleman
11.5 Irreversible Electroporation (IRE) Prostate Ablation
Ashley G. Winter
Jonathan A. Coleman
12.1 Quality of Life With Surgery
Alana M. Murphy
Patrick J. Shenot
12.2 Quality of Life With Androgen Deprivation Therapy
Alana M. Murphy
Patrick J. Shenot
12.3 Quality of Life With External Beam Radiation Therapy
Steve K. Williams
Sameer Chopra
Farhang Rabbani
12.4 Quality of Life With Brachytherapy for Low-Risk Localized Prostate Cancer
Steve K. Williams
Farhang Rabbani
13 Role for Comparative Effectiveness Research in Treatment Decision Making
Ryan T. Jones
Mark V. Mishra
Timothy N. Showalter
14 Defining Treatment Failure for Localized Prostate Cancer: PSA and Beyond
Nicholas G. Zaorsky
Robert B. Den
Jianqing Lin
15 Prognosis After Biochemical Failure and Surrogate Endpoints for Prostate CancerñSpecific Mortality
Peter Orio
Nathan Bittner
III.
Treatment for High-Risk, Localized, and Locally Advanced Disease
16 Treatment of High-Risk Prostate Cancer: The Role of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy
Thomas J. Pugh
IV.
Treatment of Disseminated Disease
17 Salvage Therapy for Rising PSA
Judd W. Moul
18 Metastatic Hormone Sensitive Prostate Cancer
Jean Hoffman-Censits
William Kevin Kelly
19.1 Metastatic Castrate-Resistant Prostate Cancer: Mechanisms of Hormone Escape
Susan F. Slovin
19.2 Metastatic Castrate-Resistant Prostate Cancer: Role of Chemotherapy and Multifaceted Treatment Paradigms
Abdel Hai Alqwasmi
Nicholas G. Zaorsky
Ulka Vaishampayan
19.3 Metastatic Castrate-Resistant Prostate Cancer: Role of Androgen Signaling Inhibitors
Austin Poole
Ajjai Alva
Julia Batten
Neeraj Agarwal
19.4.1 Radiation and the Immune System
Andrew Sharabi
Charles Drake
19.4.2 Immunotherapy: Agents Targeting Prostate Cancer
Gurveen Kaur
Naveed H. Akhtar
Beerinder K. Singh
Scott T. Tagawa
19.5 Treatment of Bony Metastases: Inhibitors of Bone Resorption
Clara Hwang
Elisabeth I. Heath
19.6 Treatment of Bone Metastases: Radiopharmaceuticals
Hossein Jadvar
Leslie Ballas
David I. Quinn
19.7 Prognostication of Metastatic Castration-Resistant Prostate Cancer
Alan D. Smith
Joaquin Mateo
Johann S. de Bono
Index
Om författaren
Nicholas G. Zaorsky, MD, is at the Department of Radiation Oncology, Fox Chase Cancer Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA.Fler e-böcker från samma författare (r) / Redaktör
142 142 E-böcker i denna kategori
